Arrowhead Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Arrowhead Pharmaceuticals's earnings have been declining at an average annual rate of -44%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 30.3% per year.
Key information
-44.0%
Earnings growth rate
-41.1%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | 30.3% |
| Return on equity | -48.2% |
| Net Margin | -70.7% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Arrowhead Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 256 | -181 | 117 | 320 |
| 31 Mar 23 | 273 | -150 | 125 | 298 |
| 31 Dec 22 | 278 | -155 | 135 | 301 |
| 30 Sep 22 | 243 | -176 | 137 | 284 |
| 30 Jun 22 | 250 | -154 | 141 | 269 |
| 31 Mar 22 | 263 | -112 | 123 | 258 |
| 31 Dec 21 | 144 | -183 | 104 | 228 |
| 30 Sep 21 | 138 | -141 | 89 | 199 |
| 30 Jun 21 | 108 | -126 | 64 | 178 |
| 31 Mar 21 | 89 | -110 | 56 | 151 |
| 31 Dec 20 | 80 | -103 | 55 | 137 |
| 30 Sep 20 | 88 | -85 | 52 | 129 |
| 30 Jun 20 | 124 | -24 | 52 | 105 |
| 31 Mar 20 | 139 | 10 | 46 | 91 |
| 31 Dec 19 | 164 | 53 | 35 | 84 |
| 30 Sep 19 | 169 | 68 | 27 | 81 |
| 30 Jun 19 | 137 | 46 | 25 | 72 |
| 31 Mar 19 | 95 | 10 | 23 | 66 |
| 31 Dec 18 | 47 | -29 | 20 | 58 |
| 30 Sep 18 | 16 | -54 | 19 | 53 |
| 30 Jun 18 | 14 | -54 | 18 | 51 |
| 31 Mar 18 | 22 | -44 | 16 | 51 |
| 31 Dec 17 | 31 | -35 | 13 | 54 |
| 30 Sep 17 | 31 | -34 | 20 | 49 |
| 30 Jun 17 | 23 | -46 | 25 | 49 |
| 31 Mar 17 | 13 | -60 | 32 | 46 |
| 31 Dec 16 | 4 | -75 | 42 | 40 |
| 30 Sep 16 | 0 | -82 | 25 | 61 |
| 30 Jun 16 | 0 | -84 | 41 | 39 |
| 31 Mar 16 | 0 | -81 | 40 | 37 |
| 31 Dec 15 | 0 | -89 | 36 | 39 |
| 30 Sep 15 | 0 | -92 | 35 | 47 |
| 30 Jun 15 | 0 | -90 | 32 | 45 |
| 31 Mar 15 | 0 | -85 | 30 | 44 |
| 31 Dec 14 | 0 | -71 | 28 | 37 |
| 30 Sep 14 | 0 | -59 | 25 | 23 |
| 30 Jun 14 | 0 | -50 | 19 | 17 |
| 31 Mar 14 | 0 | -44 | 16 | 13 |
| 31 Dec 13 | 0 | -37 | 13 | 10 |
| 30 Sep 13 | 0 | -31 | 12 | 8 |
| 30 Jun 13 | 0 | -23 | 12 | 7 |
| 31 Mar 13 | 0 | -25 | 14 | 7 |
| 31 Dec 12 | 0 | -23 | 14 | 6 |
Quality Earnings: ARWR * is currently unprofitable.
Growing Profit Margin: ARWR * is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ARWR * is unprofitable, and losses have increased over the past 5 years at a rate of 44% per year.
Accelerating Growth: Unable to compare ARWR *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARWR * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.8%).
Return on Equity
High ROE: ARWR * has a negative Return on Equity (-48.22%), as it is currently unprofitable.